Free Trial

Femasys Q4 2023 Earnings Report

Femasys logo
$1.19 -0.04 (-3.25%)
As of 04/4/2025 04:00 PM Eastern

Femasys EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.19
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Femasys Revenue Results

Actual Revenue
$0.21 million
Expected Revenue
$0.30 million
Beat/Miss
Missed by -$90.00 thousand
YoY Revenue Growth
N/A

Femasys Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Remove Ads

Femasys Earnings Headlines

Femasys (NASDAQ:FEMY) Receives "Buy" Rating from HC Wainwright
Femasys reports FY24 EPS (85c), consensus (81c)
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Femasys enters partnership with CNY Fertility
See More Femasys Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Femasys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Femasys and other key companies, straight to your email.

About Femasys

Femasys (NASDAQ:FEMY), a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

View Femasys Profile

More Earnings Resources from MarketBeat